Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INHALE-3: Afrezza + Degludec vs Usual Care in T1D
NCT05904743Phase 4Completed
- Sponsor
- MannKind
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D), sponsored by MannKind. Started Jul 2023; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05904743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904743.